The use of drugs for cardioversion of recent onset atrial fibrillation and flutter: Focus on ibutilide

Owen A. Obel, A. John Camm

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia, particularly in the elderly population. It is well recognised that AF is a major cause of stroke, even in the absence of underlying heart disease. Although AF and atrial flutter share many causes and may be seen in the same patient, there are differences between these arrhythmias: atrial flutter is less common, and the risk of stroke associated with it is less than that with AF. In addition to stroke, both AF and atrial flutter may cause cardiomyopathy, which may be fully reversible with effective treatment of the arrhythmia. Both AF and atrial flutter can result in severe symptoms and may precipitate heart failure, ischaemia and syncope. Recent research indicates that AF is a self-perpetuating arrhythmia, and that the longer it is left untreated the less likely it is that effective cardioversion will be possible. Drugs are an attractive option for the cardioversion of AF and atrial flutter because their use does not require anaesthesia. Antiarrhythmic drugs in class III of the Vaughan-Williams classification are effective in the treatment of AF, but they have adverse effects; several new 'pure' class III agents are under development. The first of these to be made available is ibutilide, a methanesulphonamide derivative. Initial results are encouraging, particularly for atrial flutter. However the drug has the potential for proarrhythmic effects and physicians who use it will need to be aware of these.

Original languageEnglish (US)
Pages (from-to)461-476
Number of pages16
JournalDrugs and Aging
Volume12
Issue number6
DOIs
StatePublished - 1998

Fingerprint

Electric Countershock
Atrial Flutter
Atrial Fibrillation
Pharmaceutical Preparations
Cardiac Arrhythmias
Stroke
ibutilide
Anti-Arrhythmia Agents
Syncope
Cardiomyopathies
Heart Diseases
Ischemia
Anesthesia
Heart Failure
Physicians

ASJC Scopus subject areas

  • Pharmacology
  • Geriatrics and Gerontology

Cite this

The use of drugs for cardioversion of recent onset atrial fibrillation and flutter : Focus on ibutilide. / Obel, Owen A.; Camm, A. John.

In: Drugs and Aging, Vol. 12, No. 6, 1998, p. 461-476.

Research output: Contribution to journalArticle

@article{030fa4407e3f465db9fbecf523f36f23,
title = "The use of drugs for cardioversion of recent onset atrial fibrillation and flutter: Focus on ibutilide",
abstract = "Atrial fibrillation (AF) is the most common sustained arrhythmia, particularly in the elderly population. It is well recognised that AF is a major cause of stroke, even in the absence of underlying heart disease. Although AF and atrial flutter share many causes and may be seen in the same patient, there are differences between these arrhythmias: atrial flutter is less common, and the risk of stroke associated with it is less than that with AF. In addition to stroke, both AF and atrial flutter may cause cardiomyopathy, which may be fully reversible with effective treatment of the arrhythmia. Both AF and atrial flutter can result in severe symptoms and may precipitate heart failure, ischaemia and syncope. Recent research indicates that AF is a self-perpetuating arrhythmia, and that the longer it is left untreated the less likely it is that effective cardioversion will be possible. Drugs are an attractive option for the cardioversion of AF and atrial flutter because their use does not require anaesthesia. Antiarrhythmic drugs in class III of the Vaughan-Williams classification are effective in the treatment of AF, but they have adverse effects; several new 'pure' class III agents are under development. The first of these to be made available is ibutilide, a methanesulphonamide derivative. Initial results are encouraging, particularly for atrial flutter. However the drug has the potential for proarrhythmic effects and physicians who use it will need to be aware of these.",
author = "Obel, {Owen A.} and Camm, {A. John}",
year = "1998",
doi = "10.2165/00002512-199812060-00004",
language = "English (US)",
volume = "12",
pages = "461--476",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - The use of drugs for cardioversion of recent onset atrial fibrillation and flutter

T2 - Focus on ibutilide

AU - Obel, Owen A.

AU - Camm, A. John

PY - 1998

Y1 - 1998

N2 - Atrial fibrillation (AF) is the most common sustained arrhythmia, particularly in the elderly population. It is well recognised that AF is a major cause of stroke, even in the absence of underlying heart disease. Although AF and atrial flutter share many causes and may be seen in the same patient, there are differences between these arrhythmias: atrial flutter is less common, and the risk of stroke associated with it is less than that with AF. In addition to stroke, both AF and atrial flutter may cause cardiomyopathy, which may be fully reversible with effective treatment of the arrhythmia. Both AF and atrial flutter can result in severe symptoms and may precipitate heart failure, ischaemia and syncope. Recent research indicates that AF is a self-perpetuating arrhythmia, and that the longer it is left untreated the less likely it is that effective cardioversion will be possible. Drugs are an attractive option for the cardioversion of AF and atrial flutter because their use does not require anaesthesia. Antiarrhythmic drugs in class III of the Vaughan-Williams classification are effective in the treatment of AF, but they have adverse effects; several new 'pure' class III agents are under development. The first of these to be made available is ibutilide, a methanesulphonamide derivative. Initial results are encouraging, particularly for atrial flutter. However the drug has the potential for proarrhythmic effects and physicians who use it will need to be aware of these.

AB - Atrial fibrillation (AF) is the most common sustained arrhythmia, particularly in the elderly population. It is well recognised that AF is a major cause of stroke, even in the absence of underlying heart disease. Although AF and atrial flutter share many causes and may be seen in the same patient, there are differences between these arrhythmias: atrial flutter is less common, and the risk of stroke associated with it is less than that with AF. In addition to stroke, both AF and atrial flutter may cause cardiomyopathy, which may be fully reversible with effective treatment of the arrhythmia. Both AF and atrial flutter can result in severe symptoms and may precipitate heart failure, ischaemia and syncope. Recent research indicates that AF is a self-perpetuating arrhythmia, and that the longer it is left untreated the less likely it is that effective cardioversion will be possible. Drugs are an attractive option for the cardioversion of AF and atrial flutter because their use does not require anaesthesia. Antiarrhythmic drugs in class III of the Vaughan-Williams classification are effective in the treatment of AF, but they have adverse effects; several new 'pure' class III agents are under development. The first of these to be made available is ibutilide, a methanesulphonamide derivative. Initial results are encouraging, particularly for atrial flutter. However the drug has the potential for proarrhythmic effects and physicians who use it will need to be aware of these.

UR - http://www.scopus.com/inward/record.url?scp=0031777363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031777363&partnerID=8YFLogxK

U2 - 10.2165/00002512-199812060-00004

DO - 10.2165/00002512-199812060-00004

M3 - Article

C2 - 9638394

AN - SCOPUS:0031777363

VL - 12

SP - 461

EP - 476

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 6

ER -